Modeling the economic value of a Chagas' disease therapeutic vaccine.

TitleModeling the economic value of a Chagas' disease therapeutic vaccine.
Publication TypeJournal Article
Year of Publication2012
AuthorsLee BY, Bacon KM, Wateska AR, Bottazzi MElena, Dumonteil E, Hotez PJ
JournalHum Vaccin Immunother
Date Published2012 Sep
KeywordsChagas Disease, Humans, Immunotherapy, Active, Latin America

The health burden of Chagas' disease (resulting from Trypanosoma cruzi infection) in Latin America (estimated to outweigh that of malaria by 5-fold and affect 2-6 million people in Mexico alone) has motivated development of therapeutic vaccines to prevent infection progression to severe disease. Our economic model for a Chagas' therapeutic vaccine in Mexico suggests that a vaccine would be highly cost-effective and in many cases economically dominant (providing both cost savings and health benefits) throughout a range of protection durations, severe adverse event risk, and dosing regimens and would be most likely to provide a positive return on investment if the vaccine prevented (rather than delayed) the onset of cardiomyopathy.

Alternate JournalHum Vaccin Immunother
PubMed ID22894964
PubMed Central IDPMC3579910
Grant List5U54GM088491-02 / GM / NIGMS NIH HHS / United States
U54 GM088491 / GM / NIGMS NIH HHS / United States
Publication Categories: